https://www.selleckchem.com/pr....oducts/paeoniflorin.
55 [95% CI 1.11-2.17]) or weight gain (hazard ratio 1.76 [95% CI 1.07-2.89]), and had increased risk of secondary outcomes (overall P 0.01) relative to ILI participants who reduced both weight and WC and relative to DSE participants. In this secondary analysis, increased WC during the first year of ILI, independent of weight change, was associated with higher risk for subsequent cardiovascular outcomes. In this secondary analysis, increased WC during the first year of ILI, independent of weight change, was associated with high
Like
Comment
Share
